What is the recommended treatment regimen for an adult with lymphocytic colitis?

Treatment for Lymphocytic Colitis in Adults

Budesonide 9 mg daily for 6-8 weeks is the first-line treatment for active lymphocytic colitis, achieving clinical remission in approximately 86-88% of patients. 1, 2

Initial Management Steps

Discontinue Offending Medications

• Stop NSAIDs immediately if the patient is taking them, as they are associated with increased incidence of microscopic colitis. 3
• Review and consider discontinuing other potentially causative medications including proton pump inhibitors and antidepressants. 4

Rule Out Infectious Causes

• Obtain stool cultures for bacterial pathogens, Clostridioides difficile toxin, and parasites at initial presentation. 3
• However, do not delay treatment while awaiting these results if the clinical picture is consistent with lymphocytic colitis. 5

First-Line Pharmacologic Therapy

Budesonide (Preferred)

• Initiate budesonide 9 mg once daily for induction of clinical remission. 1, 2, 5
• Treatment duration should be 6-8 weeks for initial induction. 1, 2
• Budesonide is more than twice as effective as placebo (RR 2.03,95% CI 1.25-3.33) for achieving clinical response. 2
• Histological remission occurs in 73-78% of patients treated with budesonide versus 31-33% with placebo. 1, 2
• Budesonide has a favorable safety profile, particularly important in elderly patients who commonly present with this condition. 5

Symptomatic Management During Induction

• Loperamide can be used for symptomatic relief while awaiting budesonide response: start with 4 mg, then 2 mg every 2-4 hours (maximum 16 mg/day). 5, 6
• Monitor for cardiac adverse reactions at higher loperamide doses, especially in older adults. 5

Alternative Treatment Options

When Budesonide Is Not Feasible

Mesalazine (Second-Line)

• Mesalazine 2.4-3 g daily may be used as an alternative, but it is approximately half as effective as budesonide for achieving clinical and histological remission. 5, 2
• Response rates with mesalazine range from 80-86% in observational studies, though controlled trial data show lower efficacy. 7, 8
• Do not use mesalazine as first-line therapy when budesonide is available, as head-to-head comparisons demonstrate clear superiority of budesonide. 5

Bismuth Subsalicylate (Third-Line)

• Bismuth subsalicylate can be considered, but supporting evidence is limited to very small trials with insufficient data to make firm recommendations. 5, 2
• May be effective in some patients based on case series. 6

Beclometasone Dipropionate

• Beclometasone dipropionate 5-10 mg daily achieves similar 8-week remission rates (84%) as mesalazine (86%), but remission is poorly maintained at 12 months (26% vs 20%). 2

Prednisolone

• Prednisolone may be employed if cost constraints preclude budesonide use, but it carries a higher systemic side-effect burden, which is particularly concerning in elderly patients. 5

Adjunctive Therapy

• Cholestyramine 4 g/day may be highly effective in patients with concomitant bile acid malabsorption, which should be suspected if diarrhea persists despite treatment. 8

Long-Term Management and Relapse

Expected Clinical Course

• Complete resolution of diarrhea is achieved in nearly all patients, with spontaneous remission occurring in approximately 20%. 8
• After initial cessation of diarrhea, 25% of patients with lymphocytic colitis will relapse after a mean follow-up of around 3 years. 8
• When relapses occur, they typically happen after a mean of 2 months following treatment discontinuation. 1

Management of Relapse

• Retreatment with budesonide is effective in patients who relapse after initial successful therapy. 1
• Consider maintenance therapy in patients with frequent relapses (see below).

Maintenance Therapy Considerations

• The evidence base for maintenance therapy in lymphocytic colitis is limited compared to collagenous colitis. 2
• For patients with frequent relapses or severe symptoms, maintenance budesonide or mesalazine may be considered, though optimal duration and dosing are not well-established. 4

Special Considerations

Associated Conditions

• Screen for thyroid disorders and celiac disease, as these autoimmune conditions commonly accompany lymphocytic colitis. 7
• In patients undergoing esophagogastroduodenoscopy, duodenal biopsies may show Marsh I villous alterations in over 10% of cases without meeting full criteria for celiac disease. 7
• Consider additional testing if patients do not respond to standard therapy to exclude coexisting celiac disease. 7

Refractory Disease

• For patients who fail budesonide therapy, biologic and small molecule treatments appear effective, though data are limited. 4
• There is an unmet need for trials with novel therapies in budesonide-refractory disease. 4

Common Pitfalls to Avoid

• Do not delay treatment while awaiting histological confirmation if the clinical picture is consistent with lymphocytic colitis; presumptive treatment with budesonide is appropriate. 5
• Do not use mesalazine as first-line therapy when budesonide is available, as efficacy is substantially lower. 5
• Do not continue NSAIDs during treatment, as they perpetuate the inflammatory process. 3
• Do not assume treatment failure without considering bile acid malabsorption as a contributing factor. 8